Recent breakthroughs in cancer immunotherapies have dramatically strengthened the fight against cancer; blocking the PD1/PDL1 axis using monoclonal antibodies has been widely used in the clinical treatment of various tumors (Li et al., 2019). This evidence concerns the gene PDCD1 and cancer.